As we near the end of another year, it falls to me to reflect on the events of 2022…
This has been a very busy year for all at Cresset, and has seen very significant pieces of news, and also continued growth in terms of the team and our expanding product portfolio, all of which comes as a result of the ongoing support we receive from our valued customers and partners.
From a personal perspective, the most important changes through the year have been to have the privilege of working with a growing, committed and talented team. We have added significantly to our global footprint, with a network of colleagues based in the UK, US, Canada, India, Japan, Italy, Spain and Macedonia, and distributors in China, Australia, South Korea and Japan.
Through the year we have seen significant scientific developments, most notably the Ignite™ technology for rapid 3D virtual screening and the Hit Expander method enabling rapid assessment of the hit-to-lead process.
Our software solutions continue to deliver innovations to advance your projects; most recently the release of Flare™ V6.1 which delivers enhanced graphics, dynamics, faster FEP analysis, updated visualizations and new powerful algorithms and methods.
We also continue to expand our footprint in being the premier in silico CRO. Cresset Discovery has delivered a record number of projects throughout the year, and has grown to be one of the biggest and best computational chemistry groups anywhere in the world. More locally, the Discovery team are proud to be collaborating with the Translation team at the Francis Crick Institute as expert computational chemist in residence.
In September we announced that we have secured investment from Scottish Equity Partners (SEP). This investment will enable us to underpin and accelerate our growth plans, and is testament to all the hard work which has gone into Cresset over the past 20 years.
We are very fortunate to work in an industry which has proven to be robust against recent negative forces, and we are optimistic for our, and your, future growth and development. This would not be possible without investment in future talent, which we continue to support through our academic offering and postdoctoral program.
I wish you all a very happy end to the year, and wish you all the very best for 2023 and our continued friendship.
Dr Robert Scoffin, CEO